-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50

Benzinga·09/10/2026 17:28:00
Listen to the news
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $46 to $50.